<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745095</url>
  </required_header>
  <id_info>
    <org_study_id>A6428-R</org_study_id>
    <secondary_id>KOR-09-10</secondary_id>
    <nct_id>NCT00745095</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage</brief_title>
  <official_title>Efficacy and Safety of Bowel Preparations for Colonoscopy in SCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The annual incidence of colorectal cancer in the US during 2005 was approximately 150,000
      cases and this neoplasm claimed 56,000 lives (American Cancer Society). Detection (and
      removal) of colonic polyps is now the central strategy in reducing the risk of colon cancer.
      Thus, failure to detect and remove small cancers and polyps can have dire consequences.
      Although it has not been shown that persons with spinal cord injury (SCI) have an increased
      risk of this disease, there is no reason to assume that the incidence after SCI would be less
      than that of the general population.

      Colonoscopy would appear to be a better approach to colon cancer screening after SCI but may
      also be unreliable if bowel evacuation is unsatisfactory for complete large bowel
      visualization. Poor colonoscopic visualization is a major concern in persons with SCI because
      they have long-standing difficulty with evacuation (DWE) and might not respond in a
      predictable or satisfactory manner to the conventional bowel preparations used for
      colonoscopy. Furthermore, to the extent that bowel preparation for colonoscopy is
      unsatisfactory in persons with SCI, the putative benefits of colonoscopy in reducing colon
      cancer mortality may not be realized.

      In the absence of effective regimens for bowel preparation in persons with SCI, we suspect
      that the documented benefits of screening colonoscopy in the able-bodied may not generalize
      to persons with SCI. Regardless, these observations support the need for improved bowel
      preparation approaches in persons with SCI. One such approach might involve the adjunctive
      administration of prokinetic drugs to standard practices. A prokinetic agent that might be
      beneficial in this context is neostigmine, an anticholinesterase inhibitor with prominent
      parasympathomimetic actions (stimulation of peristalsis) on the colon. We have studied
      neostigmine extensively in persons with SCI and have shown that, when given in combination
      with glycopyrrolate, this approach to stimulate bowel evacuation is safe and effective for
      bowel evacuation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The annual incidence of colorectal cancer in the US during 2005 was approximately 150,000
      cases and this neoplasm claimed 56,000 lives (American Cancer Society). Detection (and
      removal) of colonic polyps is now the central strategy in reducing the risk of colon cancer.
      Thus, failure to detect and remove small cancers and polyps can have dire consequences.
      Although it has not been shown that persons with spinal cord injury (SCI) have an increased
      risk of this disease, there is no reason to assume that the incidence after SCI would be less
      than that of the general population.

      Colonoscopy would appear to be a better approach to colon cancer screening after SCI but may
      also be unreliable if bowel evacuation is unsatisfactory for complete large bowel
      visualization. Poor colonoscopic visualization is a major concern in persons with SCI because
      they have long-standing difficulty with evacuation (DWE) and might not respond in a
      predictable or satisfactory manner to the conventional bowel preparations used for
      colonoscopy. Furthermore, to the extent that bowel preparation for colonoscopy is
      unsatisfactory in persons with SCI, the putative benefits of colonoscopy in reducing colon
      cancer mortality may not be realized.

      In the absence of effective regimens for bowel preparation in persons with SCI, we suspect
      that the documented benefits of screening colonoscopy in the able-bodied may not generalize
      to persons with SCI. Regardless, these observations support the need for improved bowel
      preparation approaches in persons with SCI. One such approach might involve the adjunctive
      administration of prokinetic drugs to standard practices. A prokinetic agent that might be
      beneficial in this context is neostigmine, an anticholinesterase inhibitor with prominent
      parasympathomimetic actions (stimulation of peristalsis) on the colon. We have studied
      neostigmine extensively in persons with SCI and have shown that, when given in combination
      with glycopyrrolate, this approach to stimulate bowel evacuation is safe and effective for
      bowel evacuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Bowel Preparation</measure>
    <time_frame>1-2 days following intervention</time_frame>
    <description>The quality of bowel preparation was determined by using the Ottawa Scale for bowel Evacuation. The range of this score is from 0 (perfectly clean and dry colon) to 14 ( a colon filled with stool and liquid). The right, mid and rectosigmoid colon were independently rated from 0-4 and fluid quality of entire colon was recorded with an additional score of 0-2. The total Ottawa Score is calculated by the sum of the independent scores of all three sections of the colon plus the fluid content.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polyp Detection</measure>
    <time_frame>Time of Study</time_frame>
    <description>The number of polyps detected during colonoscopic procedures were recorded and compared to each bowel cleansing preparation.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>SCI MoviPrep® (without NG)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)&lt;=50ml/min and SCI, GFR&gt;=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCI PIEE (without NG)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)&gt;=50ml/min) pulsed irrigation enhanced evacuation [PIEE] (without neostigmine plus glycopyrrolate [NG])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control MoviPrep® only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(Control, glomerular filtration rate (GFR)&gt;=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control PIEE only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(Control, glomerular filtration rate (GFR)&gt;=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCI MoviPrep® (with NG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)&lt;=50ml/min and SCI GFR&gt;=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCI PIEE (with NG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)&gt;=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
    <arm_group_label>SCI MoviPrep® (with NG)</arm_group_label>
    <arm_group_label>SCI PIEE (with NG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. SCI and able-bodied patients with clinical indication for a colonoscopic examination

        Exclusion Criteria:

          1. Able-bodied patients with a GFR 50ml/min.

          2. SCI and able-bodied patients who are not candidates for elective colonoscopy (i.e.,
             those with recent myocardial infarction, terminal illness, etc.)

          3. SCI and able-bodied patients who have a contraindication to PEG and/or ascorbic acid
             administration (i.e., those with colonic obstruction, etc.)

          4. SCI and able-bodied patients who have a contraindication for magnesium citrate (i.e.,
             those with poor renal function, class 2 or greater symptomatic heart failure, ascites)

          5. SCI and able-bodied patients with a history of bradyarrhythmia, active coronary artery
             disease or asthma will also be excluded from receiving neostigmine/glycopyrrolate

          6. Known hypersensitivity to neostigmine or glycopyrrolate

          7. Potential for pregnancy. Women who are sexually active and of childbearing potential
             (i.e. not surgically sterile or at least 2 years postmenopausal) must have negative
             serum pregnancy test.)

          8. Lactating/nursing females

          9. SCI patients with known adverse reactions to per-rectal colonic lavage.

         10. SCI patients with a serum sodium &lt;130 mM.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A. Korsten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <results_first_submitted>April 18, 2014</results_first_submitted>
  <results_first_submitted_qc>May 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2014</results_first_posted>
  <last_update_submitted>July 2, 2014</last_update_submitted>
  <last_update_submitted_qc>July 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>PIEE</keyword>
  <keyword>MoviPrep</keyword>
  <keyword>Neostigmine</keyword>
  <keyword>Glycopyrrolate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SCI MoviPrep® (Without NG)</title>
          <description>(Spinal Cord Injury [SCI], glomerular filtration rate [GFR]&lt;=50 and SCI, GFR&gt;=50) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])</description>
        </group>
        <group group_id="P2">
          <title>SCI MoviPrep® (With NG)</title>
          <description>(Spinal Cord Injury [SCI], glomerular filtration rate [GFR]&lt;=50ml/min and SCI, GFR&gt;=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
        </group>
        <group group_id="P3">
          <title>SCI PIEE (Without NG)</title>
          <description>(Spinal Cord Injury [SCI], glomerular filtration rate [GFR]&gt;=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (without neostigmine plus glycopyrrolate [NG])</description>
        </group>
        <group group_id="P4">
          <title>SCI PIEE (With NG)</title>
          <description>(Spinal Cord Injury [SCI], glomerular filtration rate [GFR]&gt;=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
        </group>
        <group group_id="P5">
          <title>Control MoviPrep® Only</title>
          <description>(Control, GFR&gt;=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] only (no neostigmine plus glycopyrrolate [NG])</description>
        </group>
        <group group_id="P6">
          <title>Control PIEE Only</title>
          <description>(Control, GFR&gt;=50ml/min) PIEE only (no neostigmine plus glycopyrrolate [NG])</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="150"/>
                <participants group_id="P6" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="122"/>
                <participants group_id="P6" count="123"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Declined to participate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible due to GFR criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCI MoviPrep® (Without NG)</title>
          <description>(SCI, GFR&lt;=50ml/min and GFR&gt;=50ml/min) MoviPrep® (without NG)</description>
        </group>
        <group group_id="B2">
          <title>SCI MoviPrep® (With NG)</title>
          <description>(SCI, GFR&lt;=50ml/min and GFR&gt;=50ml/min) MoviPrep® (without NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
        </group>
        <group group_id="B3">
          <title>SCI PIEE (Without NG)</title>
          <description>(SCI, GFR&gt;=50ml/min) PIEE ( without NG)</description>
        </group>
        <group group_id="B4">
          <title>SCI PIEE (With NG)</title>
          <description>(SCI, GFR&gt;=50ml/min) PIEE (with NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
        </group>
        <group group_id="B5">
          <title>Control MoviPrep® Only</title>
          <description>(Control, GFR&gt;=50ml/min) MoviPrep® only (no NG)</description>
        </group>
        <group group_id="B6">
          <title>Control PIEE Only</title>
          <description>(Control, GFR&gt;=50ml/min) PIEE only (no NG)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="27"/>
            <count group_id="B7" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="8"/>
                    <measurement group_id="B2" value="65" spread="6"/>
                    <measurement group_id="B3" value="61" spread="11"/>
                    <measurement group_id="B4" value="58" spread="5"/>
                    <measurement group_id="B5" value="58" spread="10"/>
                    <measurement group_id="B6" value="60" spread="9"/>
                    <measurement group_id="B7" value="60" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Bowel Preparation</title>
        <description>The quality of bowel preparation was determined by using the Ottawa Scale for bowel Evacuation. The range of this score is from 0 (perfectly clean and dry colon) to 14 ( a colon filled with stool and liquid). The right, mid and rectosigmoid colon were independently rated from 0-4 and fluid quality of entire colon was recorded with an additional score of 0-2. The total Ottawa Score is calculated by the sum of the independent scores of all three sections of the colon plus the fluid content.</description>
        <time_frame>1-2 days following intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SCI MoviPrep® (Without NG)</title>
            <description>(SCI, GFR&lt;=50 and GFR &gt;=50) MoviPrep® (without NG)</description>
          </group>
          <group group_id="O2">
            <title>SCI MoviPrep® (With NG)</title>
            <description>(SCI, GFR&lt;=50ml/min and GFR &gt;=50ml/min) MoviPrep® (withNG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
          </group>
          <group group_id="O3">
            <title>SCI PIEE (Without NG)</title>
            <description>(SCI, GFR&gt;=50ml/min) PIEE (without NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
          </group>
          <group group_id="O4">
            <title>SCI PIEE (With NG)</title>
            <description>(SCI, GFR&gt;=50ml/min) PIEE (with NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
          </group>
          <group group_id="O5">
            <title>Control MoviPrep® Only</title>
            <description>(Control, GFR&gt;=50ml/min) MoviPrep® only (no NG)</description>
          </group>
          <group group_id="O6">
            <title>Control PIEE Only</title>
            <description>(Control, GFR&gt;=50ml/min) PIEE only (no NG)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Bowel Preparation</title>
          <description>The quality of bowel preparation was determined by using the Ottawa Scale for bowel Evacuation. The range of this score is from 0 (perfectly clean and dry colon) to 14 ( a colon filled with stool and liquid). The right, mid and rectosigmoid colon were independently rated from 0-4 and fluid quality of entire colon was recorded with an additional score of 0-2. The total Ottawa Score is calculated by the sum of the independent scores of all three sections of the colon plus the fluid content.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.6"/>
                    <measurement group_id="O2" value="2.5" spread="2.4"/>
                    <measurement group_id="O3" value="3.6" spread="3.1"/>
                    <measurement group_id="O4" value="7.4" spread="5.0"/>
                    <measurement group_id="O5" value="1.8" spread="1.9"/>
                    <measurement group_id="O6" value="6.9" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Polyp Detection</title>
        <description>The number of polyps detected during colonoscopic procedures were recorded and compared to each bowel cleansing preparation.</description>
        <time_frame>Time of Study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SCI MoviPrep® (Without NG)</title>
            <description>(SCI, GFR&lt;=50ml/min and GFR &gt;=50ml/min) MoviPrep® ( without NG)</description>
          </group>
          <group group_id="O2">
            <title>SCI MoviPrep® (With NG)</title>
            <description>(SCI, GFR&lt;=50ml/min and GFR &gt;=50ml/min) MoviPrep® (with NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
          </group>
          <group group_id="O3">
            <title>SCI PIEE ( Without NG)</title>
            <description>(SCI, GFR&gt;=50ml/min) PIEE ( without NG)</description>
          </group>
          <group group_id="O4">
            <title>SCI PIEE (With NG)</title>
            <description>(SCI, GFR&gt;=50ml/min) PIEE (with NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
          </group>
          <group group_id="O5">
            <title>Control MoviPrep® Only</title>
            <description>(Control, GFR&gt;=50ml/min) MoviPrep® only (no NG)</description>
          </group>
          <group group_id="O6">
            <title>Control PIEE Only</title>
            <description>(Control, GFR&gt;=50ml/min) PIEE only (no NG)</description>
          </group>
        </group_list>
        <measure>
          <title>Polyp Detection</title>
          <description>The number of polyps detected during colonoscopic procedures were recorded and compared to each bowel cleansing preparation.</description>
          <units>Number of polyps detected (numerical)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.7"/>
                    <measurement group_id="O2" value="1.3" spread="1.5"/>
                    <measurement group_id="O3" value="0.4" spread="1.2"/>
                    <measurement group_id="O4" value="0.5" spread="1.2"/>
                    <measurement group_id="O5" value="0.9" spread="1.0"/>
                    <measurement group_id="O6" value="0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SCI MoviPrep® (Without NG)</title>
          <description>(SCI, GFR&lt;=50ml/min and GFR &gt;=50ml/min) MoviPrep (without NG)</description>
        </group>
        <group group_id="E2">
          <title>SCI MoviPrep® (With NG)</title>
          <description>(SCI, GFR&lt;=50ml/min and GFR &gt;=50ml/min) MoviPrep (with NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
        </group>
        <group group_id="E3">
          <title>SCI PIEE (Without NG)</title>
          <description>(SCI, GFR&gt;=50ml/min) PIEE ( without NG)</description>
        </group>
        <group group_id="E4">
          <title>SCI PIEE (With NG)</title>
          <description>(SCI, GFR&gt;=50ml/min) PIEE (with NG)
Neostigmine: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established</description>
        </group>
        <group group_id="E5">
          <title>Control MoviPrep® Only</title>
          <description>(Control, GFR&gt;=50ml/min) MoviPrep® only (no NG)</description>
        </group>
        <group group_id="E6">
          <title>SCI PIEE Only</title>
          <description>(Control, GFR&gt;=50ml/min) PIEE only (no NG)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>This account was unrelated to study participation since the subject passed away years after their completion. However since the subject passed away while the the study was open, this event was recorded.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Problems</sub_title>
                <description>Possibly related to the subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI discomfort, bloating, distention</sub_title>
                <description>Symptoms reported by patients during study participation</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Unable to complete preparation</sub_title>
                <description>Patients who were unable to successfully have a proper and complete bowel evacuation prior to colonoscopy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark A. Korsten, Chief of Gastroenterology</name_or_title>
      <organization>JJPVAMC National Center of Excellence for the Medical Consequeunces of Spinal Cord Injury</organization>
      <phone>718-584-9000 ext 6753</phone>
      <email>mark.korsten@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

